Navigation Links
Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties' Misleading Patent Assertions
Date:12/19/2011

repeatedly over nearly eight years to obtain a broader scope, but the USPTO rejected all of those attempts because multiple other researchers (including Dr. Liau and NW Bio) had already used dendritic cell treatments in a wide variety of sequences and timings with chemotherapies years before the Cedars Sinai/IMUC patent application was filed.  

Simply stated, NW Bio's DCVax product and treatment regimen do not fall within the narrow sequence and timing covered by the '090 patent.  The purpose and focus of NW Bio's clinical trials is to prove that DCVax is an effective treatment on its own.  Moreover, when NW Bio's DCVax reaches commercialization, the treating physician, not NW Bio, will be the party who administers DCVax, and who determines what further treatment to use in the event of recurrence.  NW Bio does not advise on post-recurrence therapies other than the use of its vaccine.  It is the physician who will determine whether to administer chemotherapy and, if so, which type of chemotherapy and in what manner. 

Additionally, all of these treatment activities can be undertaken by the physician free of the '090 patent in a variety of ways.  For example, step (b) of the patent was narrowed following USPTO rejections so as to include only the specific drugs listed. This list does not include the chemotherapy that doctors usually prescribe today after glioma recurrence (Avastin). 

  • The '090 patent is not applicable to treatment for most types of cancer.

Cedars Sinai/IMUC application sought a patent for "treating a disease condition in a mammal" but this was rejected by the USPTO.  Indeed, the USPTO would not even allow coverage of all cancers, or even all cancers of the central nervous system.  The patent claim was narrowed to just "treating a glioma in a mammal."  Glioma is only one of multiple sub-types of one cancer:  pr
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Northwestern chemists take gold, mass-produce Beijing Olympic logo
2. Northwest Secures US$1.0 Million Debt Financing
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. Northwest Biotherapeutics Secures $700,000 Equity Financing
7. Sirius Genomics to Present at Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
11. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , October 24, 2014 Investor-Edge ... (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... on these five companies can be accessed at: ... October 23, 2014, ended on a positive note as ...
(Date:10/22/2014)... , Oct. 22, 2014  Actavis plc (NYSE: ... company, and Rhythm, a biopharmaceutical company, today announced that ... Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., which is ... treatment of diabetic gastroparesis and other GI functional disorders. ... 2 trial of relamorelin for the treatment of diabetic ...
(Date:10/22/2014)... 2014 WriteResult, LLC – a ... been working with a team of researchers from Yale ... Community Farming Collaborative to provide electronic questionnaire data collection ... study, which started in May, aims to evaluate the ... weekly exposure to and participation in urban agriculture to ...
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, announced today ... a Notice of Allowance for a composition of matter ... C. difficile program, SYN-004. This is Synthetic Biologics, ... the U.S. and adds to the Company,s extensive ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
... Calif., March 30 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... shareholders, prospective investors and interested parties in Zurich, Switzerland ... will be to update the investment community on the ... be available to answer shareholder questions along with ...
... Amicus Therapeutics (Nasdaq: FOLD ) today announced ... be presenting at the upcoming 16th ... at New York City,s Millennium Broadway Hotel and Conference Center. ... April 2, 2009 at 9:30 a.m. EDT.Individuals can listen to ...
... Graeme Clark Scholarship WinnersDENVER, March 30 Cochlear ... today announced the winners of the 2009 Graeme ... Cochlear Scholarship Foundation has recognized the remarkable achievements ... implant - a small electronic device that can ...
Cached Biology Technology:Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland 2Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 2Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 3Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 4Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education 5
(Date:10/16/2014)... thinking on how the bowel lining develops and, in ... cancer starts. , The researchers produced evidence that stem ... that are a feature of the bowel lining, and ... development, a controversial finding as scientists are still divided ... technologies, Dr Chin Wee Tan and Professor Tony Burgess ...
(Date:10/16/2014)... respiratory tract infections and worldwide claims the lives ... and Ghent University have succeeded in developing a ... infection. , Xavier Saelens (VIB/UGent): "We discovered ... for the development of a novel approach to ... in numerous small children and elderly people." , ...
(Date:10/16/2014)... 16, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... including Wocket™, the Smart Wallet, at the 13 th ... a leading global conference on the intersection of technology ... Mark Anderson , founder and publisher of the Strategic ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... honors four leaders in biomedical and health informatics ... Annual Symposium, Oct. 22-26, an event expected to ... over the coming week. The Signature Awards highlight ... sector have had significant, positive impact. , ...
... 20 OCTOBER 2011 EMBO today acknowledges the outstanding ... by awarding them life-long EMBO membership. Election to ... excellence and the exceptional achievements made by a life ... 1,500 of the best researchers in Europe and around ...
... COLUMBIA, Mo. The face and brain develop ... the embryo and continuing through adolescence. Now, University of ... characteristics of children with autism compared to those of ... the origins of autism. "There is ...
Cached Biology News:AMIA honors informatics professionals who are improving health, changing the world 2AMIA honors informatics professionals who are improving health, changing the world 346 outstanding life scientists elected to EMBO membership 2Autistic facial characteristics identified 2
... Genome-pULSe Kit delivers a novel procedure for ... labeling of whole genome DNA from small ... provide a quick and highly reproducible amplification ... consists of a REPLI-g Mini Kit module ...
... Introduction of a protein into cells permits ... signaling pathways, apoptotic pathways, and transcription factor-mediated ... studying the effects of a specific protein ... the protein directly into the cell. ProteoJuice ...
... ST-190-XY is an automated instrument with a ... in real-time using light or fluorescence microscopy. ... muscle, and fibroblast cells can be simulated ... X and Y axis of our strain ...
... Our Smart Solutions has now entered the ... (HCS) by partnering up with Cellomics, Inc. ... the integration of Beckman Coulter‘s automated solutions ... deeper biological information at the sub-cellular level. ...
Biology Products: